Genentech faces crucial Avastin decision

South San Francisco-based Genentech is nearing a crucial final decision from the FDA on the use of Avastin for breast cancer. An approval, notes the San Francisco Business Times, could boost its revenue by a billion dollars a year. If regulators agree with an advisory committee's recommendation against Avastin, though, the biotech giant stands to lose out big time in the breast cancer market. Genentech currently earns significant revenue from physicians' use of the drug as a therapy for breast cancer--money that is likely to evaporate rapidly with any rejection of its application.

- see this release
- read the story from the San Francisco Business Times

Related Articles:
Genentech's blistering growth starts to cool. Report
Will FDA care about new Avastin study? Report
EU blesses Avastin for broader use. Report
FDA: Avastin lackluster in breast cancer. Report
Avastin re-submitted to FDA. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.